Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
Sponsor: Haystack Oncology, Inc.
A NA clinical study on Breast Cancer and Lymph Node Metastasis, this trial is actively recruiting participants. The trial is conducted by Haystack Oncology, Inc. and has accumulated 5 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
Phase: None → NA
-
Nov 2025 — Feb 2026 [monthly]
Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Oct 2025 [monthly]
Not Yet Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Haystack Oncology, Inc.
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .